Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Treatment with AMG 420, an Anti-B-Cell Maturation Antigen (BCMA) Bispecific T-Cell Engager (BiTE ® ) Antibody Construct, Induces Minimal Residual Disease (MRD) Negative Complete Responses in Relapsed and/or Refractory (R/R) Multiple Myeloma (MM) Patients: Results of a First-in-Human (FIH) Phase I Dose Escalation Study

Max S. Topp, Johannes Duell, MD, Gerhard Zugmaier, Michel Attal, Philippe Moreau, Christian Langer, Jan Kroenke, MD, Thierry Facon, Hermann Einsele, Gerd Munzert, MD

Blood (2018) 132 (Supplement 1): 1010.

https://doi.org/10.1182/blood-2018-99-109769

Published: 2018

Journal Articles

Phase I/II Study of BI 2536, An Intravenous Polo-Like Kinase-1 (Plk-1) Inhibitor, in Elderly Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): First Results of a Multi-Center Trial

C. Müller-Tidow, MD, Gesine Bug, MD, Richard Schlenk, MD, Michael Lübbert, MD, PhD, Alwin Krämer, MD, Juergen Krauter, MD, David Nachbaur, MD, Peter Valent, MD, Tillmann Taube, MD, Gerd Munzert, MD, Kang-Hun Lee, MD, Hartmut Dohner, MD

Blood (2008) 112 (11): 2973.

https://doi.org/10.1182/blood.V112.11.2973.2973

Published: 2008

Journal Articles

Polo-Like Kinase-1 (Plk-1) Inhibitor BI 2536 Induces Mitotic Arrest and Apoptosis in Vivo: First Demonstration of Target Inhibition in the Bone Marrow of AML Patients

Kang-Hun Lee, MD, Richard F. Schlenk, MD, Gesine Bug, MD, Carsten Müller-Tidow, MD, Ralph M. Waesch, MD, David Nachbaur, MD, Peter Valent, MD, Gerd Munzert, MD, Frank Fleischer, PhD, Hartmut Dohner, MD, PhD, Pilar Garin-Chesa, PhD

Blood (2008) 112 (11): 2641.

https://doi.org/10.1182/blood.V112.11.2641.2641

Published: 2008

Journal Articles

Phase I Dose-Escalation Trial of BI 2536, a Polo-Like Kinase 1 Inhibitor, in Relapsed and Refractory Non-Hodgkin’s Lymphoma

Julie M. Vose, Anas Young, Jonathan W. Friedberg, Edmund K. Waller, Bruce D. Cheson, Dirk Trommeshauser, Gerd Munzert

Blood (2008) 112 (11): 233.

https://doi.org/10.1182/blood.V112.11.233.233

Published: 2008

Journal Articles

Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroups

Guido Bisping, Martin Kropff, Doris Wenning, Britta Dreyer, Sergey Bessonov, Frank Hilberg, Gerald J. Roth, Gerd Munzert, Martin Stefanic, Matthias Stelljes, Christian Scheffold, Carsten Müller-Tidow, Peter Liebisch, Nicola Lang, Jöelle Tchinda, Hubert L. Serve, Rolf M. Mesters, Wolfgang E. Berdel, Joachim Kienast

Blood (2006) 107 (5): 2079–2089.

https://doi.org/10.1182/blood-2004-11-4250

Published: 2006

Journal Articles

Enhanced Anti-Myeloma Activity by Combination of Receptor Tyrosine Kinase (RTK) Inhibition, Proteasome Inhibition, and Dexamethasone: Therapeutic Implications for t(4;14) and t(14;16) Multiple Myeloma (MM) Subgroups.

Guido Bisping, MD, Doris Wenning, Martin H. Kropff, MD, Gerd Munzert, MD, Frank Hilberg, PhD, Gerald J. Roth, PhD, Wolfgang E. Berdel, MD, Joachim Kienast, MD

Blood (2005) 106 (11): 112.

https://doi.org/10.1182/blood.V106.11.112.112

Published: 2005

Journal Articles

Tumor necrosis factor receptor-associated factor 1 gene overexpression in B-cell chronic lymphocytic leukemia: analysis of NF-κB/Rel–regulated inhibitors of apoptosis

Gerd Munzert, Dieter Kirchner, Heike Stobbe, Lothar Bergmann, Roland M. Schmid, Hartmut Döhner, Hermann Heimpel

Blood (2002) 100 (10): 3749–3756.

https://doi.org/10.1182/blood.V100.10.3749

Published: 2002

Journal Articles

Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis

Beate Gleißner, Nicola Gökbuget, Claus R. Bartram, Bart Janssen, Harald Rieder, Johannes W. G. Janssen, Christa Fonatsch, Axel Heyll, Dimitris Voliotis, Joachim Beck, Thomas Lipp, Gerd Munzert, Jürgen Maurer, Dieter Hoelzer, Eckhard Thiel, the German Multicenter Trials of Adult Acute Lymphoblastic Leukemia Study Group

Blood (2002) 99 (5): 1536–1543.

https://doi.org/10.1182/blood.V99.5.1536

Published: 2002

Journal Articles

Rhenium 188–labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study

Donald Bunjes, Inga Buchmann, Christian Duncker, Ulrike Seitz, Jörg Kotzerke, Markus Wiesneth, Dagmar Dohr, Martin Stefanic, Andreas Buck, Stefanie V. Harsdorf, Gerhard Glatting, Wolfgang Grimminger, Tunca Karakas, Gerd Munzert, Hartmut Döhner, Lothar Bergmann, Sven N. Reske

Blood (2001) 98 (3): 565–572.

https://doi.org/10.1182/blood.V98.3.565

Published: 2001

NARROW

Phase I/II Study of BI 2536, An Intravenous Polo-Like Kinase-1 (Plk-1) Inhibitor, in Elderly Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): First Results of a Multi-Center Trial

Polo-Like Kinase-1 (Plk-1) Inhibitor BI 2536 Induces Mitotic Arrest and Apoptosis in Vivo: First Demonstration of Target Inhibition in the Bone Marrow of AML Patients

Phase I Dose-Escalation Trial of BI 2536, a Polo-Like Kinase 1 Inhibitor, in Relapsed and Refractory Non-Hodgkin’s Lymphoma

Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroups

Enhanced Anti-Myeloma Activity by Combination of Receptor Tyrosine Kinase (RTK) Inhibition, Proteasome Inhibition, and Dexamethasone: Therapeutic Implications for t(4;14) and t(14;16) Multiple Myeloma (MM) Subgroups.

Tumor necrosis factor receptor-associated factor 1 gene overexpression in B-cell chronic lymphocytic leukemia: analysis of NF-κB/Rel–regulated inhibitors of apoptosis

Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis

Rhenium 188–labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only